Natural Killer (NK) cells are the body's first line of innate immune defence, capable of recognising and destroying cancer cells without prior sensitisation. 23C combines activated NK cell infusion with mesenchymal stem cell therapy as an adjunct to conventional oncology treatment.
Cell therapy at 23C is positioned as a complement to conventional cancer care, not a substitute. Surgery, chemotherapy, radiation, and immunotherapy remain the backbone of cancer treatment. What cell therapy offers is support, for the immune system, for the healthy tissues affected by treatment, and for long-term recurrence prevention.
NK cells are unique, unlike other immune cells they can eliminate abnormal or stressed cells without prior exposure, and they preferentially target cancer cells while sparing healthy ones. Combined with MSC therapy for systemic recovery, this is immune-aware oncology support.
Natural Killer cells are harvested from the patient or a donor, expanded and activated in the lab over 1 to 2 weeks with substances like interleukin-2, then reinfused intravenously. The aim is to strengthen the body's cancer surveillance as an adjunct to conventional treatment.
Used alongside surgery, chemotherapy, radiation, or existing immunotherapy regimens. The goal is synergistic support, helping the immune system recognise and respond to residual or circulating cancer cells that conventional treatment may miss.
After primary treatment, enhanced NK cell activity may help reduce the risk of recurrence by improving the body's ability to detect and eliminate newly emerging abnormal cells. A supportive strategy for patients in remission.
Chemotherapy and radiation can suppress healthy tissue alongside cancer cells. MSC therapy supports tissue repair, immune reconstitution, and reduction of chronic inflammation during the recovery period.
NK cell therapy is generally low-burden with relatively minimal side effects compared to other immunotherapies like CAR-T or checkpoint inhibitors. Most patients receive treatment on an outpatient basis, with occasional mild fever or fatigue after infusion.
Lymphocytes are collected from the patient or donor, then cultured and activated over 1 to 2 weeks with interleukin-2 and interferon-gamma. The resulting NK cells are returned to the patient via IV infusion in a combat-ready state.
Treatment is coordinated with the patient's oncologist and timed to complement the chemotherapy, radiation, or immunotherapy schedule. Not a replacement for conventional care, a science-backed addition to it.
Wharton's Jelly UC-MSCs may be used alongside NK cell therapy to support tissue repair and immune reconstitution, particularly during or after treatment cycles that suppress the body's own regenerative capacity.
The following improvements have been reported by past patients. Results vary by individual, improvements cannot be guaranteed.
Cell therapy works best alongside conventional oncology care, not in place of it. Share your diagnosis, treatment plan, and current oncologist's contact so we can coordinate. Our medical team will assess how NK cell and MSC therapy may support your specific case.
Request a Case Review